Drug Profile
Research programme: antimicrobial peptides - AnGes /Morishita Jintan
Alternative Names: AG-30Latest Information Update: 03 Jan 2020
Price :
$50
*
At a glance
- Originator AnGes MG; Morishita Jintan
- Developer AnGes; Morishita Jintan
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 03 Jan 2020 AnGes MG is now called AnGes
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections(Prevention) in Japan (Topical)